News
The day at a glance · 4 min read
Mood · Risk-Off Rotation
+68
Sentiment, −100 to +100
Eli Lilly Session Gain
4%+4%
Healthcare Market Overview
Pfizer Dividend Yield
6.3%
Big Pharma & Biotech
Intuitive Surgical 1-Month Gain
12%+12%
MedTech & Devices
Key driverHealthcare stocks attracted defensive buying amid hotter inflation data, with major pharmaceutical names rallying sharply on Wednesday
Daily briefHealthcare· Money365.Market AI ·

Healthcare Rallies as Defensive Bid Lifts Big Pharma

Eli Lilly, Merck, and AbbVie surge amid market rotation; Dexcom publishes landmark Type 2 diabetes trial; Liquidia settles patent dispute.

Healthcare Market Overview

Bullish
LLYMRKABBV
01LLY
Eli Lilly (LLY) rose roughly 4% on Wednesday, joining a broad rally in healthcare stocks as investors rotated into defensive sectors following hotter September inflation data.
02
Pharma caught a bid as inflation revived Federal Reserve rate hike expectations, prompting a flight from growth sectors into more defensive healthcare names.
03LLY
Lilly (LLY), Merck (MRK), and AbbVie (ABBV) all surged, with Lilly shares rallying above their 50-day moving average to mark their best level since August.
04
The broader market showed rotation into healthcare as the Nasdaq Composite dropped 1.65% while pharmaceutical stocks outperformed significantly.

Big Pharma & Biotech

Neutral
01PFE
Pfizer (PFE) hit a 52-week high, with insider purchases, a multibillion-dollar acquisition, and progress in vaccine research helping drive investor interest. The stock now yields 6.3%, making it a focus of high-yield dividend comparisons.
02REGN
Regeneron Pharmaceuticals (REGN) may receive its next boost from an old deal rather than a new drug, according to analysis. Through the first half of 2026, Regeneron was paying down a balance owed to its partner Sanofi, an obligation that reduced the revenue Regeneron reported from the partnership.
03MRK▲ +3.80%
Merck (MRK) received positive quality investing analysis highlighting strong return on invested capital, cash conversion, and low debt relative to free cash flow, though the analysis noted revenue growth misses a key screening threshold.
04BMY▲ +4.61%
Bristol-Myers Squibb (BMY) was included in analysis of four dividend stocks that passed the 2020 stress test by continuing to raise dividends even as the pandemic hammered their sectors, with all four companies still raising dividends today.

Biotech Partnerships & Clinical Developments

Bullish
GILD
01GILD▲ +3.80%
Gilead Sciences (GILD) announced a collaboration with Vir Biotechnology to develop novel T cell engagers for solid tumors. The agreement grants Gilead exclusive rights to further develop and commercialize T cell engager candidates using Vir's technology platform, with Vir's expertise in immunology and antibody engineering applied to create targeted therapies aimed at patients with solid tumor cancers.
02
Phanes Therapeutics announced that the first patient has been dosed in the clinical study of spevatamig for the treatment of colorectal cancer. The clinical-stage biotech company is focused on innovative drug discovery and development in immuno-oncology.
03
Roche expands its obesity pipeline with a novel RNAi candidate targeting ALK7, while advancing enicepatide and other late-stage drugs to strengthen its metabolic disease ambitions.

MedTech & Devices

Bullish

Boston Scientific P/E

17.2x

Boston Scientific Price

$43.31
01DXCM
DexCom (DXCM) announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine, providing rigorous evidence of the significant benefits of continuous glucose monitoring for adults with Type 2 diabetes not on insulin. The publication represents a potential redefinition of the standard of care for people with Type 2 diabetes not on insulin.
02ISRG
Intuitive Surgical (ISRG) shares have surged nearly 12% in a month ahead of third-quarter earnings. Strong da Vinci 5 adoption and Ion growth are fueling momentum for the surgical robotics leader, though valuation and risks remain considerations for investors.
03BSX
Boston Scientific (BSX) stock currently trades at 17.2 times earnings, compared to an average multiple of 55.9 over the last twelve quarter-ends excluding readings above one hundred, according to valuation analysis. The stock closed at $43.31 as investors evaluate potential three-year returns.

Health Insurance & Managed Care

Neutral

UnitedHealth 3-Month Decline

10%-10%

Wall Street Price Target Upside

40%+40%
01UNH▲ +4.73%
UnitedHealth (UNH) has shed members and slipped 10% over three months, closing lower despite beating earnings estimates and raising guidance. A major Wall Street firm is now calling for 40% gains, with the bullish argument centered on a business unit most investors are not watching closely enough, according to the bank's analysis.

Patent Litigation & Settlements

Bearish

Liquidia 1-Month Decline

59%-59%

S&P 500 1-Month Gain

2.5%+2.5%

Liquidia Post-Ruling Drop

50%-50%
01LQDA
Liquidia (LQDA) shares have lost 59% over the past month, even as the S&P 500 gained 2.5%. The stock dropped nearly 50% on September 30 after a federal judge ruled that Yutrepia, Liquidia's inhaled lung drug, infringes a United Therapeutics patent. Liquidia subsequently settled all pending litigation with United Therapeutics on October 13, stating that Yutrepia will remain available to patients with pulmonary arterial hypertension without disruption.

AI & Drug Discovery

Neutral
TMO
01
While artificial intelligence can design prospective drug molecules in seconds, validating whether they work still depends on slow physical wet-lab testing and custom testing tools, according to analysis on investing in AI drug discovery.
02TMO
Thermo Fisher Scientific (TMO) was mentioned in the context of laboratory equipment and testing infrastructure supporting AI-driven drug discovery efforts.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy